Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Resource utilisation and quality of life following initiation of insulin detemir in patients with type 2 diabetes mellitus.

Liebl A, Andersen H, Svendsen AL, Vora J, Yale JF; SOLVE Study Group.

Int J Clin Pract. 2013 Aug;67(8):740-9. doi: 10.1111/ijcp.12133.

PMID:
23869677
[PubMed - indexed for MEDLINE]
2.

[Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].

Liebl A, Wilhelm B, Kaiser M.

MMW Fortschr Med. 2012 Dec 17;154 Suppl 4:102-9. German.

PMID:
23326928
[PubMed - indexed for MEDLINE]
3.

Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.

Vora J, Caputo S, Damci T, Orozco-Beltran D, Pan C, Svendsen AL, Sølje KS, Khunti K; SOLVE study group.

J Clin Pharm Ther. 2014 Apr;39(2):136-43. doi: 10.1111/jcpt.12116. Epub 2013 Dec 13.

PMID:
24329524
[PubMed - indexed for MEDLINE]
4.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

PMID:
20646668
[PubMed - indexed for MEDLINE]
Free Article
5.

Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.

Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC.

J Clin Endocrinol Metab. 2012 Oct;97(10):3504-14. doi: 10.1210/jc.2012-1763. Epub 2012 Jul 31.

PMID:
22851487
[PubMed - indexed for MEDLINE]
6.

Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.

Khunti K, Damci T, Meneghini L, Pan CY, Yale JF; SOLVE Study Group.

Diabetes Obes Metab. 2012 Jul;14(7):654-61. doi: 10.1111/j.1463-1326.2012.01602.x. Epub 2012 Apr 22.

PMID:
22443213
[PubMed - indexed for MEDLINE]
7.

Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).

Karnieli E, Baeres FM, Dzida G, Ji Q, Ligthelm R, Ross S, Svendsen AL, Yale JF; SOLVE Study Group.

Drugs Aging. 2013 Mar;30(3):167-75. doi: 10.1007/s40266-013-0054-3.

PMID:
23371395
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Insulin detemir: a review of its use in the management of diabetes mellitus.

Keating GM.

Drugs. 2012 Dec 3;72(17):2255-87. doi: 10.2165/11470200-000000000-00000. Review.

PMID:
23110609
[PubMed - indexed for MEDLINE]
9.

Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.

Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.

Pediatr Diabetes. 2013 May;14(3):196-202. doi: 10.1111/pedi.12012. Epub 2013 Jan 4.

PMID:
23289822
[PubMed - indexed for MEDLINE]
10.

Strategies for insulin initiation: insights from the French LIGHT observational study.

Vergès B, Brun JM, Tawil C, Alexandre B, Kerlan V.

Diabetes Metab Res Rev. 2012 Jan;28(1):97-105. doi: 10.1002/dmrr.1288.

PMID:
22218757
[PubMed - indexed for MEDLINE]
11.

An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.

Fujii H, Watanabe Y, Ueki A, Ohno A, Kato M, Kondo K, Takamura H, Takesue M, Nishimura H, Matsuda D, Miyakawa T.

Int J Clin Pract. 2010 Oct;64(11):1512-9. doi: 10.1111/j.1742-1241.2010.02391.x.

PMID:
20678116
[PubMed - indexed for MEDLINE]
12.

A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.

Bowering K, Reed VA, Felicio JS, Landry J, Ji L, Oliveira J.

Diabet Med. 2012 Sep;29(9):e263-72. doi: 10.1111/j.1464-5491.2012.03722.x. Erratum in: Diabet Med. 2012 Nov;29(11):1473. Felicio, J [corrected to Felicio, J S].

PMID:
22672081
[PubMed - indexed for MEDLINE]
13.

Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.

Soewondo P, Kshanti IA, Pramono RB, Langi YA, Dalem-Pemayun TG.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S47-53. doi: 10.1016/S0168-8227(13)70010-X.

PMID:
23647719
[PubMed - indexed for MEDLINE]
14.

Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.

Tripathi S, Chandalia HB, Rao PV, Badgandi M, Patni R, Subbanna PK, Shetty R, Kumar H.

J Indian Med Assoc. 2011 Apr;109(4):275-8.

PMID:
22187803
[PubMed - indexed for MEDLINE]
15.

Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study.

Gómez-Peralta F, Carramiñana-Barrera F, Félix-Redondo FJ, Fraile-Gómez J; Extreme Rescue Study Group.

Int J Clin Pract. 2012 Oct;66(10):959-68. doi: 10.1111/j.1742-1241.2012.03000.x.

PMID:
22994330
[PubMed - indexed for MEDLINE]
16.

Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes.

Swinnen SG, Snoek FJ, Dain MP, DeVries JH, Hoekstra JB, Holleman F.

Diabetes Technol Ther. 2009 Nov;11(11):739-43. doi: 10.1089/dia.2009.0044.

PMID:
19905891
[PubMed - indexed for MEDLINE]
17.

Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.

Koivisto V, Cleall S, Pontiroli AE, Giugliano D.

Diabetes Obes Metab. 2011 Dec;13(12):1149-57. doi: 10.1111/j.1463-1326.2011.01484.x.

PMID:
21819517
[PubMed - indexed for MEDLINE]
18.

Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice.

Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini LF, Svendsen AL; SOLVE Study Group.

Endocr Pract. 2013 May-Jun;19(3):462-70. doi: 10.4158/EP12269.OR.

PMID:
23337147
[PubMed - indexed for MEDLINE]
19.

Safety and effectiveness of insulin detemir in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

Soewondo P, Mohamed M, Jain AB, Sy RA, Khoo CM.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S10-6. doi: 10.1016/S0168-8227(13)70004-4.

PMID:
23647712
[PubMed - indexed for MEDLINE]
20.

A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.

Xie L, Wei W, Pan C, Du J, Baser O.

Adv Ther. 2011 Nov;28(11):1000-11. doi: 10.1007/s12325-011-0074-5. Epub 2011 Oct 27.

PMID:
22038703
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk